Lightcast raised $27 million to advance Envisia, its massively parallel droplet-based single-cell functional assay platform. The company said the funding will support commercialization of Envisia, aimed at enabling functional readouts from large numbers of single cells. Single-cell functional assays are used to probe cell behavior and drug responses at high throughput, typically by linking cellular phenotypes to genetic or biochemical perturbations. Lightcast’s focus on droplet-based massively parallel methods targets scalability in functional experimentation. The funding adds to the growing competitive landscape for single-cell enabling technologies used by biotech for target discovery, pathway mapping, and translational research.